REFERENCES

1. Kornbluth AA, Salomon P, Sacks HS, et al. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993;16:215-8.

2. Meyers S, Janowitz HD. The “Natural History” of ulcerative colitis: An analysis of the placebo response. Am J Gastroenterol 1989;11:33-7.

3. Calkins BM. Inflammatory bowel diseases. In: Everhart JE, ed. Digestive Diseases in the United States. Epidemiology and Impact. National Institute of Health, 1994.

4. Waye JD. Endoscopy in inflammatory bowel disease. In: Kirsner JD, Shorter RG, ed. Inflammatory bowel disease. Philadelphia: Lea and Fabiger, 1988, pp 353-76.

5. Surawicz SM, Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984;86:104-13.
6. Nostrant TT, Kumar NB, Appelman HD. Histopathology differentiates self-limited colitis from ulcerative colitis. Gastroenterology 1987;92:318-28.

7. Surawicz CM. Differential diagnosis of colitis. In: Targan SR, Shanahan F., eds. Inflammatory Bowel Disease. From Bench to Bedside. Baltimore: Williams and Wilkins, 1994; pp 409-28.

8. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;2:1041-5.

9. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-9.

10. Hanauer SB. Medical therapy of ulcerative colitis. Lancet 1993;1:412-7.

11. Baron JH, Connell JE, Lennard-Jones J, et al. Sulphasalazine and salicylazophadimidine in ulcerative colitis. Lancet 1962;1:1094-6.

12. Dick AP, Grayson MJ, Carpenter RG, et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964;5:437-42.

13. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: A multi-center study. Ann Intern Med 1991;115:350-5.

14. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic therapy for mildly to moderately ulcerative colitis: A randomized trial. N Engl J Med 1987;317:1625-9.

15. Zinberg J, Molinas S, Das KM. Double-blind, placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 1990;85:562-6.

16. Feurle GE, Theuer D, Velasco S, et al. Olsalazine versus placebo in the treatment of mild-moderate ulcerative colitis: A randomized double-blind trial. Gut 1989;30:1354-61.

17. Rao SS, Dundas SA, Holdsworth CD, et al. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut 1989;30:675-9.

18. Meyers S, Sachar DB, Present DH, et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine: A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987;93:2255-62.

19. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant to sulfasalazine. Scand J Gastroenterol 1987;22:332-7.

20. Giaffer MH, O’Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulfasalazine. Aliment Pharmacol Ther 1992;6:51-61.

21. Campieri M, Defranchis R, Bianchi G, et al. Mesalazine (5-ASA) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. Scand J. Gastroenterol 1990;25:663-8.

22. D’Arienzo A, Panarese A, D’Armiento FP, et al. 5-aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: A double-blind placebo controlled clinical trial. Am J Gastroenterol 1990;85:1079-82.

23. Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enemas in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 1987;92:1894-8.

24. Sutherland LR, Martin F. 5-aminosalicylic acid enemas in the maintenance of remission in distal ulcerative colitis and proctitis. Am J Gastroenterol 1987;1:3-6.

25. D’Albasio G, Trallori G, Ghetti A, et al. Intermittent therapy with high dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990;33:394-7.

26. Marshall JK, Irvine EJ. Topical aminosalicylic (ASA) therapy for distal ulcerative colitis: A meta-analysis. Gastroenterology 1994;106:A1037 (abstract).

27. Biddle WL, Greenberger NJ, Swan JT, et al. 5-aminosalicylic acid enemas: Effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988;94:1075-9.

28. Sutherland LR. Topical treatment of ulcerative colitis. Med Clin North Am 1990;74:119-31.

29. Watkinson G. Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate. Br Med J 1958;2:1077-82.

30. Truelove SC, Treatment of ulcerative colitis with local hemisuccinate sodium: A report on a controlled clinical trial. Br Med J 1958;2:1072-7.

31. Campiere M, Lanfranchi GA, Bazzochi G, et al. Treatment of ulcerative colitis with high dose 5-ASA enemas. Lancet 1981;2:270-3.

32. Friedman LS, Richter JM, Kirkham SE, et al. 5-ASA enemas in refractory distal ulcerative colitis: A randomized controlled trial. Am J Gastro 1986;81:412-6.

33. Danish Budesonide Study Group. Budesonide in distal colitis. Scand J Gastroenterol 1991;26:1225-9.

34. Farthing JJ, Rutland JD, Clar JL. Retrograde spread of hydrocortisone-containing foam given intrarectally in ulcerative colitis. Br Med J 1979;2:1822-7.

35. Jay M. Retrograde spreading of hydrocortisone enema in inflammatory bowel disease. Dig Dis Sci 1986;31:139-44.

36. Chapman NJ. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc 1992;67:245-8.

37. Friedman LS, Richter JM, Kirkham SE, et al. 5-ASA enemas in refractory distal ulcerative colitis: A randomized controlled trial. Am J Gastroenterol 1986;81:412-6.

38. Hanauer SB, Schwartz J, Robinson M, et al. Mesalamine capsules (Pentasa) for treatment of active ulcerative colitis: Results of a controlled trial. Am J Gastroenterol 1993;88:1188-97.

39. Willoughby CP, Cowan RE, Gould SR. Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scand J Gastroenterol (suppl) 1988;148:40-4.

40. Truelove SC, Witts IJ. Cortisone in ulcerative colitis: Report on a therapeutic trial. Br Med J 1955;2:1041-9.

41. Lennard-Jones JE. An assessment of prednisone, salazopyrine, and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960;1:217-22.

42. Baron JH. Outpatient treatment of ulcerative colitis. Br Med J 1962;2:441-4.

43. Meyers S. Oral and parenteral corticoids. In: Peppercorn M, ed. Therapy of Inflammatory Bowel Disease. New medical and surgical approaches. New York: Marcel Dekker, Inc., 1990, pp 1-34.

44. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982;284:1291-2.

45. Rosenberg JL, Wall AJ, Settles RH, et al. A controlled trial of azathropine in the treatment of chronic ulcerative colitis. Gastroenterology 1973;64:793-801.

46. Liang LC, Rubin PH, Bodian G, et al. 6-mercaptopurine is an effective steroid-sparing agent in the treatment of refractory ulcerative colitis. Gastroenterology 1992;102:A653 (abstract).

47. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990;85:717-22.

48. Lobo AJ, Foster PN, Burke D, et al. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990;33:374-7.

49. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305:20-2.

50. George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-Mercaptopurine. Am J Gastroenterol 2006;91:1711-4.

51. Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8.

52. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 1973;14:923-6.

53. Azad Khan AK, Howes DT, Piris J, et al. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980;21:232-40.

54. Sandberg-Gertzen H, Jarnerot G, Draaz W. Azodisal sodium in the treatment of ulcerative colitis: A study of tolerance and relapse-prevention properties. Gastroenterology 1986;90:1024-30.

55. Ireland A, Jewell DP. Olsalzine in patients intolerant of SASP. Scand J Gastroenterol 1989;22:1038-40.

56. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5-aminosalicylic acid, (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gut 1988;29:669-74.

57. Dew MJ, Hughes P, Harries AD, et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J 1982;285:1012-4.

58. Dew MJ, Harries AD, Evans N, et al. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. Br Med J 1983;287:413-5.

59. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988;94:1383-9.

60. Mulder CJJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988;95:1449-53.

61. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1989;3:183-91.

62. Bianchi Porro G, Ardizzone S, Fasoli R, et al. Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis. Gut 1989;30:A1467 (abstract).

63. Gionchetti P, Campieri M, Beluzzi A, et al. Pentasa in maintenance treatment of ulcerative colitis. Gastroenterology 1990;98:251-5 (letter).

64. Green JRB, Swan CHJ, Rowlinson A, et al. Comparison doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992;6:647-52.

65. Sachar DB. Maintenance therapy in ulcerative colitis and Crohn’s disease. J Clin Gastroenterol (in press).

66. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995;40:296-304.

67. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance of ulcerative colitis. Gut 1988;29:835-7.

68. Killerich S, Ladefoged K, Rennem T, et al. Prophylactic effects of olsalazine v sulphasalazine during 12 months of maintenance treatment of ulcerative colitis. Gut 1992;33:252-5.

69. Rijk MCM, Van Lier HJJ, van Tongeren JHM. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: A prospective, double-blind, randomized multicenter trial. Am J Gastroenterol 1992;87:438-42.

70. McIntyre P, Rodriges CA, Lennard-Jones JE, et al. Balasalzide in the maintenance treatment of patients with ulcerative colitis: A double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988;2:237-43.

71. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther 1989;3:183-91.

72. Travis SPL, Tysk C, Jarnerot G, et al. A dose-ranging study of olsalazine in ulcerative colitis. Gut 1992;33:546-9.

73. Giaffer H, Holdsworth CD, Lennard-Jones JE, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4G/day compared to 2G/day. Aliment Pharmacol Ther 1992;6:479-85.

74. Fockens P, Mulder CJJ, Ferwerda J, et al. Relapse prevention of ulcerative colitis: Double-blind comparison of 1.5 gram vs 3 gram oral mesalazine (Pentasa). Gastroenterology 1993;104:A701 (abstract).

75. Hanauer S, Powers B, Robinson M, et al. Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo. Gastroenterology 1994;106:A696 (abstract).

76. Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dose-finding study of olsalazine vs sulfasalazine for maintenance therapy of ulcerative colitis (abstract). Gastroenterology 1992;102:A649.

77. Green JRB, Swan CHJ, Rowlinson A, et al. Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992;6:647-52.

78. Truelove SC, Jewell D. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-70.

79. Truelove SC, Willoughby CP, Lee G, et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2:1086-8.

80. Jarnerot G, Rolny P, Saulbergh-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13.

81. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in ulcerative colitis. Gut 1986;27:1210-2.

82. Meyers S, Sachar DB, Goldberg JD, et al. Corticotropin vs hydrocortisone in the intravenous treatment of ulcerative colitis. Gastroenterology 1983;85:351-7.

83. Kaplan HP, Portnoy B, Binder HJ, et al. A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. Gastroenterology 1975;69:91-5.

84. Powell-Tuck J, Bucknell NA, Lennard-Jones JE. A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis. Scand J Gastroenterol 1977;12:971-5.

85. Rosenberg W, Ireland A, Jewell D. High-dose methylprednisone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990;12:40-1.

86. Dickinson RJ, O’Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380-4.

87. Dickinson RJ, Ashton MG, Axon ATR, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980;79:1199-2006.

88. McIntyre DB, Powell-Tuck J, Wood SR. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986;27:481-5.

89. Roediger WE. The starved colon-diminished mucosal nutrition, diminished absorption and colitis. Dis Colon Rectum 1990;33:858-62.

90. Kornbluth A, Marion J, Bharuca S, et al. The treatment of severe ulcerative and Crohn’s colitis: A critical analysis of the defined trials. J Clin Gastroenterol 1995;18:242-6.

91. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.

92. Kornbluth A, Lichtiger S, Present DH, et al. Long term results of oral cyclosporine in patients with severe ulcerative colitis: A double-blind, randomized, multi-center trial. Gastroenterology 1994;106(2):A714 (abstract).

93. Present DH, Wolfson D, Gelernt IM, et al. Medical decompression of toxic megacolon by “rolling.” J Clin Gastroenterol 1988;10:485-90.

94. Panos MS, Wood MJ, Asquith P. Toxic megacolon: The knee-elbow position relieves bowel distension. Gut 1993;34:1726-7.

95. Truelove SC, Mark CG. Toxic Megacolon. Clin Gastroenterol 1981;10:107-17.

96. Korelitz BI, Dyck WP, Klion FM. Fate of the rectum and distal colon after subtotal colectomy for ulcerative colitis. Gut 1969;10:198-201.

97. Robert JH, Sachar DB, Aufses AH, et al. Management of severe hemorrhage in ulcerative colitis. Am J Surg 1990;159:550-5.

98. Greenstein AJ, Sachar DB, Gorbas A, et al. Outcome of toxic dilation in ulcerative and Crohn’s colitis. J Clin Gastroenterol 1985;7:137-44.

99. Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colorectal cancer in ulcerative colitis. Gastroenterology 1985;89:1342.

100. Nugent FW, Haggit RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991;100:1241-8.

101. Blackstone M, Riddell RW, Rogers BHG, et al. Dysplasia associated lesion or mass (DALM) detected by colonoscopy in longstanding ulcerative colitis: An indication for colectomy. Gastroenterology 1981;80:366-74.

102. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992;33:938-41.

103. Reiser JR, Waye JD, Janowitz HD, et al. Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy. Am J Gastroenterol 1994;89:119-22.

104. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis. Lancet 1994;343:71-4.

105. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-44.

106. Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: The predictive value of low grade dysplasia. Gastroenterology 1992;103:431-8.

107. Talansky A, Meyers S, Greenstein AJ, et al. Does intestinal resection heal the pyoderma of inflammatory bowel disease? J Clin Gastroenterol 1983;5:207-10.

108. Altman AR, Maltz CR, Janowitz HD. Autoimmune hemolytic anemia in ulcerative colitis. Dig Dis Sci 1979;24:282-5.

109. Arner O. Autoimmune hemolytic anemia in ulcerative colitis cured by colectomy. Acta Med Scand 1971;189:275-8.

110. Greenstein AJ, Sachar DB, Smith H, et al. Cancer in ulcerative and left-sided ulcerative colitis: Factors determining risk. Gastroenterology 1979;77:290-4.

111. Sugita A, Sachar DB, Bodian C, et al. Colorectal cancer in ulcerative colitis: Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 1991;32:167-9.

112. Gilat T, Fireman Z, Grossman A, et al. Colorectal cancer in patients with ulcerative colitis: A population study in central Israel. Gastroenterology 1988;94:870-7.

113. Sachar DB. Cancer risk in inflammatory bowel disease: Myths and Metaphors. In: Riddel RH, ed. Dysplasia and cancer in colitis. New York: Elsevier, 1991, pp 5-9.

114. Greenstein AJ, Sachar DB, Pucillo A, et al. Cancer in universal and left-sided ulcerative colitis: Clinical and pathological features. Mt Sinai J Med 1979;46:25-32.

115. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: A cohort study of primary referrals from three centers. Gut 1988;29:206-17.

116. Greenstein AJ, Slater G, Heimann TM, et al. Comparison of multiple synchronous colorectal cancers in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg 1986;203:123-8.

117. Vemulapalli R, Lance P. Cancer surveillance in ulcerative colitis: More of the same or progress? Gastroenterology 1994;107:1196-9.

118. Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis: Results from a surveillance program. Dig Dis Sci 1989;10:1536-41.

119. Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: Comparison with clinical outcome. Hum Pathol 1989;20:1008-14.

About

So Many Advances in Medicine, So Many Yet to Come